Brainomix is a pioneering medical software company specializing in AI-powered imaging solutions that enhance precision medicine and improve treatment decisions for patients worldwide. Founded as a spin-out from the University of Oxford, Brainomix has developed the Brainomix 360 Stroke platform, the world's first fully automated AI-imaging solution for acute stroke assessment. This platform supports both simple and advanced imaging needs, empowering healthcare providers to make faster, more confident treatment decisions, thereby improving patient outcomes. Building on this success, Brainomix has expanded its AI technology into other therapeutic areas, including lung fibrosis and cancer, aiming to transform diagnosis and treatment where it matters most.
Key Features and Functionality:
- Comprehensive Stroke Imaging: The Brainomix 360 Stroke platform offers a suite of tools, including e-ASPECTS, e-CTA, e-CTP, and e-MRI, providing real-time interpretation of brain scans to support clinicians at every stage of the patient journey.
- AI-Driven Biomarkers: Brainomix's technology automates validated imaging biomarkers, enabling precise assessment of conditions such as ischemic core volume from non-contrast CT scans, facilitating more confident treatment and transfer decisions.
- Lung Fibrosis Assessment: The e-Lung platform applies AI-driven CT biomarkers to identify, monitor, and predict disease progression in pulmonary fibrosis, supporting clinical development efforts for treatments like ILD and IPF.
- Multiple Sclerosis Solution: Through a partnership with Pixyl, Brainomix distributes the Neuro.MS SaaS solution, which automatically analyzes brain MRI images to identify, quantify, and track abnormalities in under five minutes, aiding in the diagnosis and treatment of multiple sclerosis.
Primary Value and User Solutions:
Brainomix's AI-powered imaging solutions address critical challenges in medical diagnostics by providing rapid, accurate, and automated assessments of complex imaging data. For stroke care, the Brainomix 360 platform has been associated with a more than 50% increase in mechanical thrombectomy rates, leading to improved patient outcomes. In lung fibrosis, the e-Lung platform enhances clinical trial outcomes by improving patient selection and efficacy assessment. By integrating AI-driven insights into routine clinical practice, Brainomix empowers healthcare providers to make informed decisions quickly, ultimately expanding access to life-saving treatments and improving patient care across multiple therapeutic areas.
